A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF).

Bejanyan, Nelli; Tiu, Ramon V; Raza, Azra; Jankowska, Ania; Kalaycio, Matt; Advani, Anjali; Chan, Josephine; Saunthararajah, Yogen; Mooney, Lindsey; Maciejewski, Jaroslaw P; Sekeres, Mikkael A

Bejanyan, Nelli; Tiu, Ramon V; Raza, Azra; Jankowska, Ania; Kalaycio, Matt; Advani, Anjali; Chan, Josephine; Saunthararajah, Yogen; Mooney, Lindsey; Maciejewski, Jaroslaw P; Sekeres, Mikkael A.

Affiliation

Bejanyan N; Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.

Cancer ; 118(16): 3968-76, 2012 Aug 15.

Article in En | MEDLINE | ID: mdl-22180010

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Myelodysplastic-Myeloproliferative Diseases / Primary Myelofibrosis Type of study: Clinical_trials Limits: Aged / Female / Humans / Male Language: En Journal: Cancer Year: 2012 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google